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ABSTRACT
A few weeks after the peak of the global 2019novel
coronavirus disease pandemic, cases of shock, multisystem
inflammation and severe myocarditis have occurred in
children and adolescents, generating some concerns and
above all many questions. An almost immediate association
raised with shock syndrome related to Kawasaki disease
(KD). However, in light of bo/th experience and literature
have taught us about severeacute respiratory syndrome
coronavirus 2 (SARS-COV-2) infection, and what already
known on the epidemiology of KD, we suggest here the
hypothesis of a new ‘post-viral’ systemic inflammatory
disease related to excessive adaptive immune response
rather than a form of KD caused by SARS-COV-2. We
discuss analogies and differences between the two forms.
INTRODUCTION
Since the last few weeks, there have been
cases in the pediatric age characterised by
shock, myocarditis and variable signs of mul-
tisystem inflammation. Cases occurred more
frequently in some areas, such as Europe and
EasternUS, where the 2019novel coronavirus
disease (COVID-19) pandemic has hit the
most. Precise epidemiological data are not
yet available, but several countries including
Italy, France, Spain and UK have started
national registries, and media attention has
risen so much that there have been concerns
even in the general population, previously
rarely aware of Kawasaki disease (KD), that
severeacute respiratory syndrome corona-
virus 2 (SARS-COV-2) could cause a vasculitis
in their children. Moreover, there have been
multiple calls to physicians and hospitals
from parents of children previously affected
with KD that they might be at higher risks.
Aim of this review is, therefore, to try to clar-
ify what the current situation stands with
regard to KD during the pandemic, in parti-
cular to its relation with to this multisystemic
inflammatory syndrome.
COVID-19 IN THE PEDIATRIC AGE
The global pandemic of COVID-19 initially
seemed to affect children only mildly.
Indeed, in March 2020, the Chinese Center
for Disease Control and Prevention reported
that the pediatric population represented
only 1% of the 72 314 cases compiled in
Wuhan, the focus of the pandemic.1 One
study evaluating 1391 children systematically
tested retrieved 171 (12.3%), confirmed with
SARS-COV-2 infection, and in whom 27
(15.8%) had neither clinical nor radiologic
symptoms. Their median age was 6.7 years
with a slight male predominance (60.8%);
pneumonia (bilateral ground-glass opacity)
and upper respiratory tract infection were
the most common features, and only one
death occurred. Later, a Chinese epidemio-
logic survey among 2135 SARS-COV-2-
exposed children gave approximately the
same findings.2 Recently, a systematic review
detailed all the published pediatric cases of
COVID-19.3 Eight hundred and fifteen arti-
cles including 18 studies with 1065 partici-
pants (444 patients younger than 10 years
and 553 aged 10–19 years) with confirmed
SARS-COV-2 infection were included in the
final analysis. Children at any age had mild
respiratory symptoms, namely fever, dry
cough and fatigue, or were even asympto-
matic. Bronchial thickening and ground-
glass opacities were the main radiologic fea-
tures. Among the included articles, there was
only one case of severe COVID-19 infection,
which occurred in a 13-month-old infant.
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As the pandemic progresses in Europe and still in line
with a benign outcome, several SARS-COV-2 related cuta-
neous features were reported in children with peculiar
attention on chilblains.4 5 This is of particular interest, as
we will discuss later, in the context of possible association
with vasculitis and considering that chilblains are one of
the hallmarks of monogenic lupus and of interferonopa-
thies, which often enters the differential diagnosis with
viral infections (eg, Aicardi-Goutieres syndrome).
ALERT OF A NEW MULTISYSTEM DISEASE POSSIBLY RELATED
TO SARS-COV-2 INFECTION
At the end of April 2020 and coming from the UK, a first
alert of severe pediatric cases referred in intensive care
unit for a feature possibly related to SARS-COV-2 and
overlapping with myocarditis and toxic shock syndrome
changed the initial idea of a favourable outcome of
COVID-19 in childhood as one of the eight patients
died. It also generated some confusion as some of the
patients presented clinical signs of KD, a medium-sized
vasculitis of young children. Since then there have been
multiple reports of similar cases, even though up to the
writing of the present review (May 15, 2020) only two
series have been published in peer-reviewed journals.6 7
The definitions of this condition now include ‘hyper-
inflammatory shock’, ‘hyper-inflammatory syndrome
with multiorgan involvement’, ‘pediatric inflammatory
multisystem syndrome (PIMS)’ (with or without the suf-
fix—TS, that is, temporally associated with SARS-COV-2),
‘Kawasaki-like syndrome’, ‘Kawasaki-like disease’. Regard-
less of the name given, we think it more important to
understand what could be its pathophysiology, its exact
clinical characteristics and best treatment options. In
light of the first published cases and the growing experi-
ence of European and American pediatric centers, it
looks that different clinical scenarios can be described,
as follows.
KAWASAKI DISEASE DURING THE PANDEMIC
The first case of concurrent COVID-19 and KD was pub-
lished by Jones et al,8 and was just the first description of a
child with classic KD, who also screened positive for
COVID-19 in the setting of fever and minimal respiratory
symptoms. There are clear-cut cases of KD (complete,
incomplete and atypical), but without shock syndrome,
that as every year are continuing to appear in all coun-
tries. Whether these cases are more prevalent during the
SARS-COV-2 pandemic is still unclear, but preliminary
unpublished data do not, in general, seem to support
this hypothesis. In fact, there are hints that the contrary
might be the case, and the fear of contracting hospital-
acquired infections might contribute to less emergency
department consultations. Indeed, an international
panel that include member of the American HeartAsso-
ciation (AHA) guidelines Committee for KD gave recom-
mendations in this regard.9 In Japan, where the incidence
of this disorder is higher than in any other country, they
surveyed members of the Japanese Society for Kawasaki
Disease. In just 2 days, 31 medical institution in 17 pre-
fectures replied, and compared to the average year the
number of patients were mostly unchanged, or even
decreased (C. Shimizu and Takahashi, personal commu-
nication). The majority answered that there was no
change in severity compared to the average year, and
there were no reports of severe cases of KD or KD-like
cases that could lead to ICU management. Due to the
relative rarity of this disease, analyses of data collected in
Europe will occur only at the end of the year, or at least
when sufficient numbers will be available.
With regard to possible links with SARS-COV-2 infec-
tion, the pathogenesis of KD is still unclear,10 11 but is the
result of an excessive immune response to unidentified
triggering agents, which could stimulate the innate
immune system with strong systemic inflammatory
response then engaging adaptive immunity leading to
organ damage.
Epidemiologic evidence of a viral role in triggering KD
is suggested by seasonal epidemics,12 and a number of
viruses such as adenovirus, rhinovirus, influenza, Boca
virus and enterovirus have been implicated.13 14 Of
note, coronaviruses are included in the list of viruses
known to trigger KD, and a high suspicion for the two
species HCoV-NH and HCoV-NL63 raised, but studies
eventually gave conflicting results.15 16 The possible role
of SARS-COV-2 in ‘classic’ KD pathogenesis has yet to be
determined but in view of what previously discussed cur-
rent evidence does not seem to support this hypothesis.
SPECTRUM OF SYSTEMIC HYPER-INFLAMMATORY FEATURES
ASSOCIATED TO SARS-COV-2 IN CHILDREN
Unusual cases of acute myocarditis with features of toxic
shock and heart failure requiring hemodynamic stabilisa-
tion in the context of marked systemic inflammation
raised first alert. Most of these children had fever, skin
rash, conjunctivitis, painful oedema at the extremities
and significant gastrointestinal symptoms. Another some-
what milder phenotype has also appeared including chil-
dren of all age groups, again with prominent
gastrointestinal symptoms but with more subtle myocar-
dial involvement. Features of macrophage activation syn-
drome with elevated ferritinaemia were seen in many
cases.
The only two published series relate to English and
Italian cases. The English case series recently been pub-
lished showed a cluster of eight patients with shock, high
inflammatory indices and different types of cardiologic
involvement.6 Six out of eight were of Afro-Caribbean
origin. The clinical features were similar: continuous
fever, rash, conjunctivitis, peripheral oedema, pain in
the extremities and significant gastrointestinal involve-
ment. Most of them did not experience significant
respiratory involvement, unlike typical COVID-19. The
Italian series7 comprised 10 patients, 8 of which were
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positive for SARS-COV-2 either by swab or by serology,
aged 2.9–16 years (mean 7.5). Myocardial involvement
and features of macrophage activation syndrome were
common in this cohort. Although patients met criteria
for typical and atypical KD, their clinical and biochemical
features differed from the historical cohort of KD patients
seen in the previous years, hence the name of Kawasaki-
like disease. Notably, all 10 patients recovered without
sequelae.
SEMANTIC CONTROVERSY AROUND CASES DEFINITION
Contrasting with classical KD, systemic inflammation
following SARS-COV-2 infection affects older children
and teenagers. Other intriguing findings are that
patients with severe forms are less commonly Caucasians
than the expected frequency in their general population
(many of African-American or Afro-Caribbean ethni-
city). In addition, such cases were not reported in
Korea and Japan; these populations have the highest
incidence of KD and SARS-COV-2 pandemic has been
present in these areas as well; hence, a genetic back-
ground for these severe cases is likely. Regarding the
clinical feature, most reported cases do not meet the
AHA’s case definition for KD or in a minority of cases
present only as incomplete forms. 17 18 Myocardial invol-
vement is a hallmark of this hyper-inflammatory state,
whereas coronary aneurysms are the hallmark of KD.
Intravenous immunoglobulins (IVIG), which are also
given frequently in other causes of myocarditis anyway,
were apparently effective in those patients. Indeed, the
immunomodulatory properties IVIG are not specific but
result in strong anti-inflammatory effect. Therefore, we
think that despite some similarities, there are epidemio-
logical, clinical and laboratory evidences that support
the concept of a new syndrome separated from KD. We
find it quite important at least in the present time since
the name Kawasaki has generated confusion in the
media and the public, and patients and families who
have suffered from this condition in the past require
reassurance. Moreover, the general population is now
aware that SARS-COV-2 can cause damage to the vessels
of children, and it is crucial to emphasise that up to now
the virus has minimal morbidity and exceptional mortal-
ity in the pediatric age. For cases with inflammatory
multisystem syndrome, the European Centers for Dis-
ease Prevention and Control has stated that overall risk
in the EU/EEA and the UK is considered low, based on a
very low probability of PIMS in children and a high
impact of such condition.19
Many of these cases occurred after several weeks of
quarantine, and it is possible that these subjects suffered
from a mild form of COVID-19 after intrafamilial trans-
mission and severe complications appeared weeks later,
likely related to a dysregulated immune response. The
temporal relationship between infection curves and
reported cases would also be consistent with this
hypothesis.
The presence of shock has led to analogies with KD
shock syndrome. Toxic shock is a rare presentation of
KD (1–2%),20 often inaugural and without the typical
mucocutaneous symptoms, but toxic shock has also
been associated for years with bacterial toxins, especially
from streptococcus and staphylococcus, playing a role of
superantigen with subsequent immunologic reaction
similar to anaphylaxis. At present, little is known on the
link between viral infection and shock syndrome. Of
interest, a retrospective cohort of 1099 SARS-COV-2 con-
firmed patients in China reported 12 (1.1%) with shock
syndrome, the direct role of the virus may, however, be
only speculative, as these patients may have had coinfec-
tions suffered from treatment-related anaphylactic
reactions.21
Moreover, we would like to stress some important
points for clinicians. Patients with fever, systemic inflam-
mation and presenting with extreme fatigue, pallor, diffi-
culty breathing, blood pressure instability, hepatomegaly
and significant digestive signs (diarrhoea, ileus) may
require early referral to intensive care units for hemody-
namic assistance and close monitoring. Elevated serum
ferritin and ProBNP, elevation of D-dimers, together with
hypoalbuminaemia, thrombocytopenia and strikingly ele-
vated acute phase reactants are in line with an intense
cytokine storm. PCR assay of SARS-COV-2 requires either
nasopharyngeal, oropharyngeal swab or stool sampling,
but search of specific antibodies may be necessary in case
PCR tests are negative. Prompt treatment with IVIG 2 g/
kgmay be effective, but as it implies infusion of large fluid
volumes, it may be preferable to infuse them divided into
two separate doses and to use preferably highly concen-
trated products. In case of obesity (BMI >30), reducing
20% of therapeutic dose may avoid renal complications
linked to the increase in oncotic pressure and blood
viscosity. Treatment with corticosteroids and in some
cases anti-IL-1 agents may be advisable even if trials can-
not justify it. Of note, in adults with severe COVID-severe
infections trials with anakinra are ongoing, and the drug
worked satisfactorily in cases of resistant KD.22 The out-
come of reported cases of KD does not seem to be any
different from in the past, and outcome of the cases with
multisystem involvement seems generally quite good with
early recognition and treatment, even if few deaths
occurred.
Finally, great uncertainty exists with regard to the exact
classification, pathogenesis, phenotypes and best treat-
ment choices for patients with a multisystem inflamma-
tory disorder possibly related to SARS-COV-2 infection.
However, science is likely to advance since many of these
cases share common features and mechanistic studies
may also be helpful to better define etiopathogenesis,
improve early recognition and identify more precise tar-
gets for treatment.
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